Increasing Macrolide and Fluoroquinolone Resistance in Mycoplasma genitalium.

July 19, 2017 at 3:56 pm

Emerg Infect Dis. May, 2017 V.23 N.5 P.809-812.

Murray GL, Bradshaw CS, Bissessor M, Danielewski J, Garland SM, Jensen JS, Fairley CK, Tabrizi SN.

Abstract

Escalating resistance to azithromycin and moxifloxacin is being reported for Mycoplasma genitalium in the Asia-Pacific region.

Analyzing 140 infections, we found pretreatment fluoroquinolone-resistance mutations in parC (13.6%) and gyrA (5%). ParC S83 changes were associated with moxifloxacin failure.

Combined macrolide/fluoroquinolone-resistance mutations were in 8.6% of specimens, for which recommended therapies would be ineffective.

PDF

https://wwwnc.cdc.gov/eid/article/23/5/pdfs/16-1745.pdf

Advertisements

Entry filed under: Antimicrobianos, Bacterias, Epidemiología, Infecciones de transmision sexual, Metodos diagnosticos, Resistencia bacteriana, Update.

Pneumocystis jiroveci pneumonia: comparative study of cases in HIV-infected patients and immunocompromised non-HIV-infected patients. The Active Component of Aspirin, Salicylic Acid, Promotes Staphylococcus aureus Biofilm Formation in a PIA-dependent Manner


Calendar

July 2017
M T W T F S S
« Jun   Aug »
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Most Recent Posts


%d bloggers like this: